| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5908838 | JOURNEY | Method for the treatment of acne |
Feb, 2018
(6 years ago) | |
| US8252776 | JOURNEY | Minocycline oral dosage forms for the treatment of acne |
Jun, 2025
(1 year, 1 month from now) | |
| US7790705 | JOURNEY | Minocycline oral dosage forms for the treatment of acne |
Jun, 2025
(1 year, 1 month from now) | |
| US8268804 | JOURNEY | Minocycline oral dosage forms for the treatment of acne |
Jun, 2025
(1 year, 1 month from now) | |
| US7919483 | JOURNEY | Method for the treatment of acne |
Mar, 2027
(2 years from now) | |
| US7544373 | JOURNEY | Minocycline oral dosage forms for the treatment of acne |
Apr, 2027
(2 years from now) | |
| US7541347 | JOURNEY | Minocycline oral dosage forms for the treatment of acne |
Apr, 2027
(2 years from now) | |
Ximino is owned by Journey.
Ximino contains Minocycline Hydrochloride.
Ximino has a total of 7 drug patents out of which 1 drug patent has expired.
Expired drug patents of Ximino are:
- US5908838
Ximino was authorised for market use on 11 July, 2012.
Ximino is available in capsule, extended release;oral dosage forms.
Ximino can be used as treatment of acne, treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.
The generics of Ximino are possible to be released after 02 April, 2027.
Drugs and Companies using MINOCYCLINE HYDROCHLORIDE ingredient
Market Authorisation Date: 11 July, 2012
Treatment: Treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris; Treatment of acne
Dosage: CAPSULE, EXTENDED RELEASE;ORAL
XIMINO family patents
